StreetAlpha.app
Home › Stocks › LXEO

Lexeo Therapeutics, Inc. (LXEO)

$2.85
▼ −11.61%
LAST CLOSE · NOV 17

Lexeo Therapeutics develops gene therapies that aim to treat inherited heart diseases in patients with genetic cardiomyopathies. It last closed at $2.85 on Nov 17, down 11.61% on the day. LXEO reports earnings on Mon, Dec 14, 2026. The average 12-month price target from 2 analysts is $26.00 (+810.7% from the last close), with a high of $37.00 and a low of $15.00.

AI Auto Pilots
Is LXEO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$105.3M
EPS (diluted)
−$1.13
Free cash flow
−$87.7M
Valuation
Market cap
$236.4M
82.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$90.2M
At Sep 30
Shareholder equity
$216.7M
Shares outstanding
82.8M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$59.3M−$59.3MFY2022FY2023: −$66.4M−$66.4MFY2023FY2024: −$98.3M−$98.3MFY2024FY2025: −$100.0M−$100.0MFY2025

From LXEO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Dec 14
2026 · Time not announced
Consensus EPS forecast
-$0.32
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated LXEO in the past 90 days, not enough for a consensus
Average 12-month target
$26.00
▲ 810.7% upside

Based on 2 analysts who set a price target on LXEO in the past 90 days. The average target is $26.00, with a high of $37.00 and a low of $15.00, compared with the last close of $2.85.

Low $15.00Avg $26.00High $37.00
Blue marker: last close $2.85
Highest target$37.00
Average target$26.00
Lowest target$15.00
Latest rating changes
Cantor FitzgeraldTarget raised
Nov 16Buy$23 → $37
Cantor FitzgeraldReiterated
Nov 12Buy$23
Leerink PartnersMaintained
Sep 23Buy$15
JP MorganMaintained
Jun 25Buy$9
DateFirmActionRatingPrice target
Nov 16Cantor FitzgeraldTarget raisedBuy$23 → $37
Nov 12Cantor FitzgeraldReiteratedBuy$23
Sep 23Leerink PartnersMaintainedBuy$15
Jun 25JP MorganMaintainedBuy$9
Loading…

Technical Analysis

LXEO · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 16% below its 50 day average. It is 73% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the swing low (Nov 6) at $2.70, and the nearest resistance the 20 day average at $3.00.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 13.1%/day
Key levels
$10.9952 week high+285.6%
$4.94200 day average+73.3%
$4.02100 day average+41.1%
$3.3150 day average+16.1%
$3.22Pivot R1+13.0%
$3.12Swing high (Oct 22)+9.5%
$3.03Pivot+6.3%
$3.0020 day average+5.3%
$2.85Last close
$2.70Swing low (Nov 6)−5.3%
$2.66Pivot S1−6.7%
$2.5552 week low−10.5%
Indicators
RSI (14)44.05Middle of its rangeNeutral
MACD-0.08Above its signal lineBullish
Stochastic23.7Middle of its rangeNeutral
ADX (14)19.6No clear trend
Williams %R-90.3Oversold below −80, overbought above −20Oversold
CCI (20)1.4Oversold below −100, overbought above 100Neutral
Rate of change−8.2%Change over 10 sessionsBearish
ATR (14)$0.38Typical daily range, 13.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LXEO

What happened before

See how LXEO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LXEO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LXEO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LXEO in the last 90 days.

Loading…

See today’s whale options flow across the market →

LXEO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲80 buying vs 55 selling
  • ▲Held by funds +2.6 pts
  • ▲Funds holding +11
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153142+7.7%
In funds' top 10110.0%
Held by funds110.7%108.2%+2.6 pts
New / increased30 / 5027 / 58−5.9%
Reduced / sold out37 / 1839 / 23−11.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LXEO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXEO is in one of them and how their past LXEO trades turned out.

LXEO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LXEO in an article yet. Here's the latest on the wider market.

About Lexeo Therapeutics

Lexeo Therapeutics is a biotechnology company based in New York that develops gene therapies for inherited heart diseases. Its candidates are designed to deliver working copies of disease-linked genes to heart muscle cells. The lead programs target Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy caused by PKP2 gene mutations, and the company is also developing candidates for other genetic heart conditions. Its target patients have genetic heart diseases with few or no approved treatments.

Headquarters
New York, NY